On the geoepidemiology of multiple sclerosis and environmental and infectious determinants of its clinical course by Simpson Jr, S




& infectious determinants of 
its clinical course 
 
By 
Steve Simpson, Jr., 
B.A., Biological Sciences (USA); 
M.P.H., Infectious Disease (USA) 
 
A thesis submitted in fulfilment of the requirements 





University of Tasmania, Hobart 
December 2011 
 Declaration of originality 
 
ii | P a g e  
 
Declaration of originality 
This thesis contains no material which has been accepted for a degree or diploma by the University of 
Tasmania, nor any other institution, except by way of background information and duly acknowledged 
in the thesis, and to the best of my knowledge and belief, no material previously published or written by 
























 Statement of authority to access 
 
iii | P a g e  
 
Statement of authority to access 
This thesis may be available for loan.  Copying of any part of this thesis is prohibited for two years from 
the date this statement was signed; after that time, limited copying is permitted in accordance with the 


























 Statement of Co-authorship 
 
iv | P a g e  
 
Statement of Co-authorship 
This thesis includes papers for which Steve Simpson, Jr. (SSJ) is not sole author.  SSJ took the lead in 
this research, developing and implementing the analyses included herein under the supervision of Leigh 
Blizzard (LB), writing manuscripts, and in the case of the meta-analysis of multiple sclerosis prevalence, 
designing and implementing the research project.  In this process, however, he was assisted by co-
authors to varying extent.  Following then, the contributions of each co-author are detailed for each 
respective project. 
1. The paper reported in Chapter 2: 
Simpson, Jr. SL, Pittas F, van der Mei I, Blizzard L, Ponsonby A-L, Taylor B. “Trends in the 
epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009.” Journal of Neurology, 
Neurosurgery & Psychiatry. Feb 2011; 82(2): 180-187. 
 
 SSJ contributed to the data collection for the 2009 prevalence data along with Bruce 
Taylor (BT), management of the 2009 prevalence data and consolidation with the 2001 
prevalence data, calculation of the 2001-2009 incidence and mortality rates; along with 
LB, statistical analysis of temporal trends in prevalence, incidence and mortality was 
done by SSJ under supervision by LB.  SSJ composed drafts of the manuscript and 
coordinated revision.  
 Fotini Pittas (FP) was involved in the development and acquisition of funding for both 
the 2001 and 2009 prevalence studies along with BT and Ingrid van der Mei (IvM); FP 
contributed to the data collection for the 2001 prevalence data along with BT; FP was 
involved in the conception of some of the analyses used in the study and contributed to 
the critical revision of the manuscript. 
 LB provided guidance and supervision for all statistical analyses undertaken in this 
study, and was involved in the initial drafting and critical revision of the manuscript. 
 Statement of Co-authorship 
 
v | P a g e  
 
 IvM was involved in the development and acquisition of funding for both the 2001 and 
2009 prevalence studies along with BT and FP; IvM was involved in the initial drafting 
and critical revision of the manuscript. 
 Anne-Louise Ponsonby (A-LP) was involved in the development and acquisition of 
funding for the 2001 prevalence study along with BT, IvM and FP, and contributed to 
the critical revision of the manuscript. 
 BT was involved in the development acquisition of funding for both the 2001 and 2009 
prevalence studies along with IvM and FP.  BT was involved in data collection for both 
the 2001 and 2009 prevalence studies.  BT was involved in the initial drafting and 
critical revision of the manuscript. 
2. The paper reported in Chapter 3: 
Simpson, Jr. SL, Blizzard, L, Otahal P, van der Mei I, Taylor B. “Latitude is significantly associated 
with the prevalence of multiple sclerosis: a meta-analysis.” Journal of Neurology, Neurosurgery & Psychiatry. 
82(10); 1132-1141. 
 
 SSJ conceived the project and collected all prevalence data required, from published 
manuscripts, conference proceedings and/or direct correspondence with study 
authors.  In concert with and under guidance of LB, Petr Otahal (PO) and BT, SSJ 
developed and implemented all statistical analyses.  SSJ composed the drafts of the 
manuscript and coordinated revision.  SSJ consolidated the data and composed the table 
in Appendix 4A.  SSJ consolidated the data and composed the initial draft and critical 
revision of Appendix 4B.  SSJ composed the initial draft and critical revision of 
Appendix 4C.  SSJ consolidated the data and composed the table in Appendix 4D.   
 LB provided guidance and supervision for all statistical analyses undertaken in this 
study, and was involved in the initial drafting and critical revision of the manuscript. 
 Statement of Co-authorship 
 
vi | P a g e  
 
 PO worked in concert with SSJ, LB and BT to develop statistical analyses undertaken in 
this study, and was involved in critical revision of the manuscript. 
 IvM was involved in the initial drafting and critical revision of the manuscript. 
 BT worked in concert with SSJ, PO, and PO to develop analyses undertaken in this 
study, and was involved in the initial drafting and critical revision of the manuscript. 
3. The paper reported in Chapter 4: 
Simpson, Jr. SL, Greenhill K, van der Mei I, Stankovich J, Charlesworth J, Taylor B. “The varied 
mechanisms of vitamin D in the onset and clinical course of MS: potential roles in modulating other 
aetiologic pathways.” Current Medical Literature – Neurology.  27(1) 1-14. 
 
 SSJ undertook the literature review for the background and immunological actions of 
vitamin D and its metabolites, epidemiology of personal UV exposure, vitamin D 
intake and circulating levels of vitamin D and their relationship with multiple sclerosis 
risk and clinical course, and the role of vitamin D in manifesting or modulating other 
causal pathways in multiple sclerosis risk and clinical course.  SSJ composed the initial 
draft of these sections and coordinated critical revision of the manuscript. 
 Kate Greenhill (KG) undertook the literature review for the background and 
intracellular and genetic actions of 1,25-dihydroxyvitamin D.  KG composed the initial 
draft of these sections and contributed to the critical revision of the manuscript.   
 IvM contributed to the critical revision of the manuscript. 
 Jim Stankovich (JS) provided guidance for KG and contributed to the critical revision 
of the manuscript. 
 Jac Charlesworth (JC) provided guidance for KG and contributed to the critical 
revision of the manuscript. 
 BT contributed to the critical revision of the manuscript. 
 
 Statement of Co-authorship 
 
vii | P a g e  
 
4. The paper reported in Chapter 5: 
Simpson Jr. SL, Taylor B, Blizzard L, Ponsonby A-L, Pittas F, Tremlett H, Dwyer T, Gies P, van der 
Mei I. “Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS.” Annals of Neurology. 
Aug 2010; 68(2): 193-203.   
 
 SSJ was involved in the development and implementation of statistical analyses 
undertaken, under supervision by LB.  SSJ composed the drafts of the manuscript and 
coordinated revision.   
 BT was involved in the development and acquisition of funding for the MS Longitudinal 
Study from which the data for this analysis was drawn, along with A-LP, FP, Terence 
Dwyer (TD), Peter Gies (PG), and IvM; BT was involved in the data collection for the 
MS Longitudinal Study, along with FP, PG, and IvM.  BT was involved in the initial 
drafting and critical revision of the manuscript. 
 LB provided guidance and supervision for all statistical analyses undertaken in this 
study, and was involved in the initial drafting and critical revision of the manuscript. 
 A-LP was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, FP, TD, PG, and IvM; A-LP contributed to the 
critical revision of the manuscript. 
 FP was involved in the development and acquisition of funding for the MS Longitudinal 
Study, along with BT, A-LP, TD, PG, and IvM.  FP was involved in the data collection 
for the MS Longitudinal Study, along with BT, PG, and IvM.  FP contributed to the 
critical revision of the manuscript. 
 Helen Tremlett (HT) was involved in the conception and implementation of the 
analyses used and contributed to the critical revision of the manuscript. 
 Statement of Co-authorship 
 
viii | P a g e  
 
 TD was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, PG, and IvM.  TD contributed to the 
critical revision of the manuscript. 
 PG was involved in the data collection for the MS Longitudinal Study, specifically the 
acquisition and reading of the polysulphone badge data.  PG contributed to the critical 
revision of the manuscript. 
 IvM was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, and TD.  IvM was involved in the data 
collection for the MS Longitudinal Study, along with BT, FP and PG.  IvM was 
involved in the conception of the analyses used.  IvM was involved in the initial drafting 
and critical revision of the manuscript.   
5. The paper reported in Chapter 6 
Simpson Jr. SL & Stewart N, van der Mei I, Eyles D, Ko P, Ponsonby A-L, Pittas F, Blizzard L, 
Dwyer T, Taylor B.  “Interferon-β is associated with higher serum 25-hydroxyvitamin D and both 
interact to modulate relapse risk in multiple sclerosis.” Neurology. In-press (Accepted 15 November 
2011). 
 
 SSJ was involved in the development and implementation of statistical analyses 
undertaken, under supervision by LB.  SSJ composed the drafts of the manuscript and 
coordinated revision.   
 NS initiated project and was involved in initial drafting and critical revision of the 
manuscript. 
 IvM was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, and TD.  IvM was involved in the data 
collection for the MS Longitudinal Study, along with BT and FP.  IvM was involved in 
the critical revision of the manuscript.   
 Statement of Co-authorship 
 
ix | P a g e  
 
 Darryl Eyles (DE) was involved in measurement of 1,25-dihydroxyvitamin D and was 
involved in critical revision of the manuscript. 
 Pauline Ko (PO) was involved in measurement of 1,25-dihydroxyvitamin D and was 
involved in critical revision of the manuscript. 
 A-LP was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, FP, TD, and IvM; A-LP contributed to the critical 
revision of the manuscript. 
 FP was involved in the development and acquisition of funding for the MS Longitudinal 
Study, along with BT, A-LP, TD, and IvM.  FP was involved in the data collection for 
the MS Longitudinal Study, along with BT and IvM.  FP contributed to the critical 
revision of the manuscript. 
 LB provided guidance and supervision for all statistical analyses undertaken in this 
study, and was involved in the initial drafting and critical revision of the manuscript. 
 TD was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, and IvM.  TD contributed to the critical 
revision of the manuscript. 
 BT was involved in the development and acquisition of funding for the MS Longitudinal 
Study from which the data for this analysis was drawn, along with A-LP, FP, TD, and 
IvM; BT was involved in the data collection for the MS Longitudinal Study, along with 
FP and IvM.  BT was involved in the initial drafting and critical revision of the 
manuscript. 
6. The paper reported in Chapter 7: 
Simpson, Jr. SL, Taylor B, Dwyer D, Taylor J, Blizzard L, Ponsonby A-L, Pittas F, Dwyer T, van der 
Mei, I. “Anti-HHV-6 IgG titers are significantly predictive of relapse risk in multiple sclerosis.” Multiple 
Sclerosis. doi: 10.1177/1352458511428081. 
 Statement of Co-authorship 
 
x | P a g e  
 
 SSJ was involved in the development and implementation of statistical analyses 
undertaken, under supervision by LB.  SSJ composed the drafts of the manuscript and 
coordinated revision.   
 BT was involved in the development and acquisition of funding for the MS Longitudinal 
Study from which the data for this analysis was drawn, along with A-LP, FP, TD, and 
IvM; BT was involved in the data collection for the MS Longitudinal Study, along with 
Dominic Dwyer (DD), Janette Taylor (JT), FP and IvM.  BT was involved in the initial 
drafting and critical revision of the manuscript. 
 DD was involved in the data collection for the MS Longitudinal Study, specifically the 
measurement of anti-human herpesvirus IgG titres, along with JT.  DD was involved in 
the critical revision of the manuscript. 
 JT was involved in the data collection for the MS Longitudinal Study, specifically the 
measurement of anti-human herpesvirus IgG titres, along with DD.  JT was involved in 
the critical revision of the manuscript. 
 LB provided guidance and supervision for all statistical analyses undertaken in this 
study, and was involved in the initial drafting and critical revision of the manuscript. 
 A-LP was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, FP, TD, and IvM; A-LP contributed to the critical 
revision of the manuscript. 
 FP was involved in the development and acquisition of funding for the MS Longitudinal 
Study, along with BT, A-LP, TD, and IvM.  FP was involved in the data collection for 
the MS Longitudinal Study, along with BT, DD, JT, and IvM.  FP contributed to the 
critical revision of the manuscript. 
 Statement of Co-authorship 
 
xi | P a g e  
 
 TD was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, and IvM.  TD contributed to the critical 
revision of the manuscript. 
 IvM was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, and TD.  IvM was involved in the data 
collection for the MS Longitudinal Study, along with BT, DD, JT and FP.  IvM was 
involved in the conception of the analyses used.  IvM was involved in the initial drafting 
and critical revision of the manuscript.   
7. The paper reported in Chapter 8: 
Simpson, Jr. SL, Taylor B, Dwyer D, Taylor J, Blizzard L, Ponsonby A-L, Pittas F, Dwyer T, van der 
Mei, I. “Serological reactivation of human herpesvirus 6 is not associated with clinical outcomes in 
multiple sclerosis.” (unsubmitted manuscript) 
 
 SSJ was involved in the development and implementation of statistical analyses 
undertaken, under supervision by LB.  SSJ composed the drafts of the manuscript and 
coordinated revision.   
 BT was involved in the development and acquisition of funding for the MS Longitudinal 
Study from which the data for this analysis was drawn, along with A-LP, FP, TD, and 
IvM; BT was involved in the data collection for the MS Longitudinal Study, along with 
Dominic Dwyer (DD), Janette Taylor (JT), FP and IvM.  BT was involved in the initial 
drafting and critical revision of the manuscript. 
 DD was involved in the data collection for the MS Longitudinal Study, specifically the 
measurement of anti-human herpesvirus IgG titres, along with JT.  DD was involved in 
the critical revision of the manuscript. 
 Statement of Co-authorship 
 
xii | P a g e  
 
 JT was involved in the data collection for the MS Longitudinal Study, specifically the 
measurement of anti-human herpesvirus IgG titres, along with DD.  JT was involved in 
the critical revision of the manuscript. 
 LB provided guidance and supervision for all statistical analyses undertaken in this 
study, and was involved in the initial drafting and critical revision of the manuscript. 
 A-LP was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, FP, TD, and IvM; A-LP contributed to the critical 
revision of the manuscript. 
 FP was involved in the development and acquisition of funding for the MS Longitudinal 
Study, along with BT, A-LP, TD, and IvM.  FP was involved in the data collection for 
the MS Longitudinal Study, along with BT, DD, JT, and IvM.  FP contributed to the 
critical revision of the manuscript. 
 TD was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, and IvM.  TD contributed to the critical 
revision of the manuscript. 
 IvM was involved in the development and acquisition of funding for the MS 
Longitudinal Study, along with BT, A-LP, FP, and TD.  IvM was involved in the data 
collection for the MS Longitudinal Study, along with BT, DD, JT and FP.  IvM was 
involved in the conception of the analyses used.  IvM was involved in the initial drafting 
and critical revision of the manuscript.   
Signed   ________________________________ Signed   ________________________________ 
 
Associated Professor Bruce Taylor 
Supervisor 
Menzies Research Institute Tasmania 
University of Tasmania 
 
Date   __________________ 
 
Professor Simon Foote 
Head of School 
Menzies Research Institute Tasmania 
University of Tasmania 
 
Date   __________________ 
 Acknowledgements 
 




I am indebted to the thorough and patient guidance and support I received from my supervisors, Bruce, 
Ingrid & Leigh, throughout the duration of my PhD.  They provided me the structure within which I 
could complete my projects, while giving me the intellectual freedom to develop my own ideas and 
projects and grow as a researcher.  For this and more, they have my sincere thanks. 
For my world outside of work, I owe my sanity and stability to my dear partner, Abel, without whom I 
would have been hard pressed to handle the stressors of life as a doctoral student.  He has always kept 
my home life happy and stable, and I have always known that whatever drama ensued during the day, I 
had his smiling face to come to.  Abel, you are my strength and anchor in life, and I’d be lost without 
you. 
Lastly, I would offer my thanks to the participants of the MS Longitudinal Study and the MS Prevalence 
& Genetics Study, as well as the innumerable participants in the studies included in my meta-analysis.  
The work we do would not exist were it not for their kind participation and giving of their time, so at 
the very least I hope that the work of my thesis in some way is of help to our participants, and all 
persons.    
 Abstract 
 
xiv | P a g e  
 
Abstract 
Multiple sclerosis (MS) is a chronic, demyelinating condition of the central nervous system, manifesting 
in alteration or loss of motor, sensory and cognitive function. The causes of MS are unclear but include 
genetic and environmental factors.  This thesis presents several epidemiologic analyses, examining MS 
geoepidemiology, locally and globally, as well as evaluating key environmental and infectious 
determinants of clinical course.   
The first analysis chapter examines MS epidemiology in the Greater Hobart region of Tasmania over the 
interval 1951 to 2009.  This analysis found a significant increase in prevalence, this mediated by a 
significantly decreased mortality and increased longevity, as well as evidence of an increasing 
female/male sex ratio. 
Next is a meta-analysis of MS prevalence and its association with latitude.  This work, utilising the 
largest collection of MS prevalence studies, found a significant positive association between MS 
prevalence and latitude. This provides evidence in favour of the latitudinal gradient hypothesis and for 
environmental factors underlying the gradient, most particularly personal ultraviolet radiation (UVR) 
exposure and vitamin D.   
The association between serum 25-hydroxyvitamin D (25(OH)D) and relapse was examined in a 
prospective cohort with clinically-definite MS followed for 2.3 years.  This analysis found a significant 
inverse association between higher levels of 25(OH)D and subsequent hazard of relapse.  This study 
provides key evidence that is needed to justify conducting randomised clinical trials of vitamin D 
supplementation in reducing relapse frequency in MS.  
In this MS cohort, it was also found that persons on interferon-β (IFN-β) therapy had significantly 
higher 25(OH)D levels and that the association between personal sun exposure and 25(OH)D was 
stronger compared to those not on IFN-β.  Importantly, the above association between 25(OH)D and 
relapse was only observed for those on IFN-β therapy.   
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Last is an examination of the role of antibodies to Human Herpesvirus 6 (HHV-6) and Epstein-Barr 
virus (EBV) in MS clinical course.  This analysis found a significant positive association between anti-
HHV-6 IgG and relapse.  This effect persisted on adjustment for the anti-EBV IgGs, indicating the effect 
was specific for HHV-6 antigen, or host antigen resembling it.  There was no evidence of frequent 
serological HHV-6 reactivation, suggesting that the observed association between anti-HHV-6 IgG and 
relapse was not being mediated by serologically-detectable peripheral reactivation of HHV-6.  No 
associations were observed between anti-HHV-6 and anti-EBV IgGs and progression in clinical 
disability.   
This thesis presents a range of studies which add significantly to the literature on MS geoepidemiology, 
as well as the associations of environmental and infectious factors on MS clinical course.  This work will 
be useful in the scientific community; both for hypothesis generation and providing strong evidence in 
support of existing hypotheses, and hopefully be of benefit to people with this debilitating disease. 
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HLA-DRB1 Most prevalent beta-subunit for Class II Major Histocompatibility 
Complex  
HR Hazard Ratio 
IFA Immunofluorescence Assay 
IFN-β Interferon beta 
IgG Immunoglobulin class G 
IgM Immunoglobulin class M 
IL Interleukin 
IQR Interquartile Range 
ISR Incidence Sex Ratio 
IU International Units 
Km Kilometers 
MET Metabolic Equivalent of Task 
MRI Magnetic Resonance Imaging 
MS Multiple Sclerosis 
MSFC Multiple Sclerosis Functional Composite 
MSL Multiple Sclerosis Longitudinal Study 
MSSS Multiple Sclerosis Severity Score 
nmol/L Nanomoles per Liter 
NSW New South Wales 
PBMC Peripheral Blood Monocyte 
PCR Polymerase Chain Reaction 
PPMS Primary-Progressive Multiple Sclerosis 
PSR Prevalence Sex Ratio 
RCT Randomised Controlled Trial 
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RRMS Relapsing-Remitting Multiple Sclerosis 
RTI Respiratory Tract Infection 
SD Standard Deviation 
SED Standard Erythemal Dose 
SPMS Secondary-Progressive Multiple Sclerosis 
TAS Tasmania 
Th1 Helper T-lymphocyte class 1 
Th2 Helper T-lymphocyte class 2 
Th17 Helper T-lymphocyte class 17 
Treg Regulatory T-lymphocyte 
WA (Australia) Western Australia 
UK United Kingdom of Great Britain and Northern Ireland 
USA United States of America 
UVR Ultraviolet radiation 
VCA Epstein-Barr Virus Viral Capsid Antigen 
VDBP Vitamin D binding protein 
VDR Vitamin D receptor 
VDRE Vitamin D receptor element 
vIL-10 viral interleukin 10 
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